Lawrence C.B. Chan, M.D., D.Sc.
Department of Medicine-Diabetes,
Endocrinology, and Metabolism
Vijay Yechoor, M.D.
Department of Medicine-Diabetes,
Endocrinology, and Metabolism
Drs. Chan and Yechoor received the award for their joint contributions to the understanding
of cell fate determination and the molecular therapy of diabetes.
In a publication in Developmental Cell in 2009, Yechoor et al. found that following
theintroduction of a single gene, Neurogenin3, cells in the liver can take on the
structure and function of the endocrine pancreas and go on to completely reverse
diabetes in mice. Yechoor and Chan also uncovered a novel mechanism for the induced
beta cell neogenesis. They found that transfer of a single transcription factor
into an endoderm-derived lineage is sufficient to cause cell lineage switching and
induce formation of neo-islets. The newly formed islets display a complete islet-specific
transcription program and produce insulin in a glucose-responsive manner, stably
reversing diabetes.
Yechoor and Chan further found that the newly formed periportal beta cells possess
are structured similarly to pancreatic beta cells. These findings shed light on
the fundamental processes of cell fate determination and reprogramming and provide
a blueprint for a potential curative therapy for insulin-deficient diabetes.
Drs. Chan and Yechoor's nomination was based on the following publications:
Yechoor V, Liu V, Espiritu C, Paul A, Oka K, Kijima H, Chan L. Neurogenin3
Is Sufficient for Transdetermination of Hepatic Progenitor Cells into Neo-Islets
In Vivo but Not Transdifferentiation of Hepatocytes. ". Developmental Cell
2009 Mar 16: 358-373.
Yechoor V, Liu V, Paul A, Lee J, Buras E, Ozer K, Samson S, Chan L. " Gene Therapy with
Neurogenin 3 and Betacellulin Reverses Major Metabolic Problems in Insulin-Deficient
Diabetic Mice. ". Endocrinology 2009 150(11); 4863-4873.